Scroll Back to Top

Taylor Jensen, PhD

Vice President, Head of Oncology Science

Dr. Taylor Jensen's role as Head of Oncology Science focuses on biomarkers, precision medicine assays, and product strategy in oncology.  After studying in the field of cancer epigenetics, Dr. Jensen joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Subsequently, he has been involved in numerous assay development efforts focused on the identification and detection of genomic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics.

Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on the development of novel technologies and assays, primarily using cfDNA, with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including the American Association for Cancer Research and the American Society of Clinical Oncology, has contributed to three patents, and has authored or co-authored more than 30 publications in peer reviewed scientific journals.  He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.